PTC Therapeutics reported Q4 and full-year 2022 results Tuesday ahead of a pivotal 2023 featuring three late-stage readouts in registration-directed trials.
Tag Archive for: Phase II/III trial
Shares of Athira Pharma climbed Monday morning as an analysis of un-blinded interim data showed its Alzheimer’s drug candidate, fosgonimeton, provided clinically meaningful improvements in cognition and function.
